118 related articles for article (PubMed ID: 10091812)
1. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
Shibata A
Cancer; 1999 Mar; 85(5):1208-10. PubMed ID: 10091812
[No Abstract] [Full Text] [Related]
2. Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?
van der Kwast TH
Eur Urol; 2006 Feb; 49(2):209-11. PubMed ID: 16417961
[No Abstract] [Full Text] [Related]
3. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
4. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
5. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
6. Characterization of minute adenocarcinomas of prostate at radical prostatectomy.
Truskinovsky AM; Sanderson H; Epstein JI
Urology; 2004 Oct; 64(4):733-7. PubMed ID: 15491711
[TBL] [Abstract][Full Text] [Related]
7. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.
Freedland SJ; deGregorio F; Sacoolidge JC; Elshimali YI; Csathy GS; Dorey F; Reiter RE; Aronson WJ
J Urol; 2003 Apr; 169(4):1325-30. PubMed ID: 12629353
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
9. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
11. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Stenman UH
Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
[No Abstract] [Full Text] [Related]
13. How valuable is prostate-specific antigen screening?
Handler S
Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
[No Abstract] [Full Text] [Related]
14. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic strategy for prostate specific antigen (PSA) failure after radical prostatectomy].
Kinoshita H; Kamoto T; Mitsumori M; Kiyokawa T; Habuchi T; Kakehi Y; Hiraoka M; Ogawa O
Gan To Kagaku Ryoho; 2003 Jan; 30(1):32-7. PubMed ID: 12557702
[TBL] [Abstract][Full Text] [Related]
16. [Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression?].
Wirth M
Urologe A; 1998 Jul; 37(4):427-8. PubMed ID: 9738298
[No Abstract] [Full Text] [Related]
17. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
18. [A case report: mucinous carcinoma of prostate].
Noma M; Mori N; Kobayashi Y; Hara T; Yamaguchi S
Hinyokika Kiyo; 2003 Oct; 49(10):591-3. PubMed ID: 14655602
[TBL] [Abstract][Full Text] [Related]
19. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
